Bendamustine - A new approach to the treatment of advanced hepatocellular carcinoma?

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 112-118

  Wiedmann, Marcus ^a   Zeh, J ^a   Schoppmeyer, K ^a   Moebius, C ^a   Niederhagen, M ^b   Wittekind, C ^a   Mossner, J ^a   Caca, K ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^c KLINIKUM LUDWIGSBURG   (Germany)

Author keywords

Bendamustine; Chemotherapy; Hepatocellular carcinoma

Indexed keywords

BENDAMUSTINE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; TUMOR VOLUME;

EID: 41149156533     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.112     Document Type: Article

References (46)

1. El-Serag HB and Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340 (10): 745-750.
2. Parkin DM, Bray F, Ferlay J, and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94 (2): 153-156.
3. Thomas MB and Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23 (13): 2892-2899.
4. Llovet JM and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37 (2): 429-442.
5. Llovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I; Vol 25, No. 18S (June 20 Supplement) LBA1.
6. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, and Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007; 55 (1): 109-113.
7. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002; 128 (11): 603-609.
8. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132 (2): 105-112.
9. Kath R, Blumenstengel K, Fricke HJ, and Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001; 127 (1): 48-54.
10. Ponisch W, Mitrou PS, Merkle K et al. Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132 (4): 205-212.
11. von Minckwitz G, Chernozemsky I, Sirakova L et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16 (8): 871-877.
12. Weidmann E, Kim SZ, Rost A et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13 (8): 1285-1289.
13. Herold M, Anger G, Hoche D, and Kastner R. [Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease]. Med Klin (Munich) 1987; 82 (10): 345-349.
14. Herold M, Siebert S, Schulze A et al. Reduced combined modalitiy treatment for Hodgkin's disease: Results of a randomized multicenter trial. Leukemia Lymphoma 1998; 29 (Suppl 1) P-85 (84th International Symposium on Hodgkin's Lymphoma; abstract).
15. Zimonjic DB, Keck CL, Thorgeirsson SS, and Popescu NC. Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology 1999; 29 (4): 1208-1214.
16. Tannapfel A, Geissler F, Kockerling F, Katalinic A, Hauss J, and Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J Pathol 1999; 187 (4): 439-445.
17. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, and Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996; 77 (1): 164-171.
18. Niemeyer C, Bendall H, Reifert J, Bailey B, and Leoni LM. Mitotic Catastrophe Induced in Tumor Cells Treated with Bendamustine (Treanda™, SDX-105). Proceedings of ASCO 2005; Abstract 2291.
19. Huang M and Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 1999; 135 (1): 97-105.
20. Kato A, Miyazaki M, Ambiru S et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001; 78 (2): 110-115.
21. Lai CL, Wu PC, Chan GC, Lok AS, and Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62 (3): 479-483.
22. Halm U, Etzrodt G, Schiefke I et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11 (1): 113-114.
23. van Eeden H, Falkson G, Burger W, and Ansell SM. 5-Fluorouracil and leucovorin in hepatocellular carcinoma. Ann Oncol 1992; 3 (5): 404-405.
24. Falkson G, Ryan LM, Johnson LA et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987; 60 (9): 2141-2145.
25. Melia WM, Johnson PJ, and Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983; 51 (2): 206-210.
26. Hochster HS, Green MD, Speyer J, Fazzini E, Blum R, and Muggia FM. 4′Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985; 3 (11): 1535-1540.
27. Lai KH, Tsai YT, Lee SD et al. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol 1989; 23 (1): 54-56.
28. Jungi WF. Etoposide single-agent chemotherapy for solid tumors. Cancer Treat Rev 1982; 9 Suppl 31-37.
29. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97 (20): 1532-1538.
30. Boucher E, Corbinais S, Brissot P, Boudjema K, and Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50 (4): 305-308.
31. Yang TS, Lin YC, Chen JS, Wang HM, and Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89 (4): 750-756.
32. Fuchs CS, Clark JW, Ryan DP et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002; 94 (12): 3186-3191.
33. Patt YZ, Hassan MM, Aguayo A et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101 (3): 578-586.
34. O'Reilly EM, Stuart KE, Sanz-Altamira PM et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001; 91 (1): 101-105.
35. Wall JG, Benedetti JK, O'Rourke MA, Natale RB, and Macdonald JS. Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs 1997; 15 (3): 257-260.
36. Chao Y, Chan WK, Birkhofer MJ et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998; 78 (1): 34-39.
37. Stuart K, Tessitore J, Rudy J, Clendennin N, and Johnston A. A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 1999; 86 (3): 410-414.
38. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26): 4293-4300.
39. Schwanen C, Hecker T, Hubinger G et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002; 16 (10): 2096-2105.
40. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, and Berger MR. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002; 128 (5): 271-278.
41. Strumberg D, Harstrick A, Doll K, Hoffmann B, and Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7 (4): 415-421.
42. Weber H, Amlacher R, Preiss R, and Hoffmann H. [Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice]. Pharmazie 1991; 46 (8): 589-591.
43. Bezek S, Kukan M, Scasnar V, Lukacsova M, and Trnovec T. Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice. Methods Find Exp Clin Pharmacol 1996; 18 (2): 117-122.
44. Teichert J, Sohr R, Baumann F et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005; 33 984-992.
45. Teichert J, Baumann F, Chao Q et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59: 759-70.
46. Schoppmeyer K, Kreth F, Wiedmann M, Mossner J, Preiss R, and Caca K. Phase I/II trial of bendamustine in advanced bile duct cancer. Anti-Cancer Drugs 2007; 18: 697-702.